CNS Pharmaceuticals, Inc. (“CNS” or the “Company”), a biotechnology company specializing in the development of novel treatments for brain tumors, announced it has signed a contract with NCK A/S for the large-scale production of Berubicin, its lead drug candidate for the treatment of glioma brain tumors.   NCK A/S is a GMP manufacturer of complex drugs located in Farum, Denmark, and the previous producer of Berubicin for Reata Pharmaceuticals. Production of large scale B...